GÖTTINGEN, Germany,
Feb. 11, 2021 /PRNewswire/ -- The
Supervisory Board of Sartorius AG resolved at its meeting today to
approve an early extension of the appointments of René Fáber as a
member of the Executive Board and Head of the
Bioprocess Solutions Division, as well as of Gerry Mackay as a member of the Executive Board
and Head of the Lab Products & Services Division.
René Fáber (45) has been working for Sartorius since 2002 and
has been an Executive Board member of Sartorius AG since
January 2019. His appointment has now
been extended by five years until December 31, 2026.
Gerry Mackay (58) joined Sartorius
in 2015 through the acquisition of BioOutsource and has been an
Executive Board member of Sartorius AG also since
January 2019. The Supervisory Board accepted Gerry Mackay's request to extend his appointment
only by two years until December 31, 2023, due to his private
plans for the future.
In addition, the Supervisory Board of Sartorius AG approved the
Executive Board's recommendation to submit a proposal to the Annual
General Shareholders' Meeting on March 26,
2021, to pay dividends for fiscal 2020 of 0.71 euros per preference share and 0.70 euros per ordinary share. Therefore, the
total amount disbursed under this proposal would be 48.2 million euros. Prior-year dividends were
0.36 euros per preference share and 0.35 euros per ordinary share.
This press release contains forward-looking statements about the
future development of the Sartorius Group. Forward-looking
statements are subject to known and unknown risks, uncertainties
and other factors that could cause actual results to differ
materially from those expressed or implied by such statements.
Sartorius assumes no liability for updating such statements in
light of new information or future events. This is a translation of
the original German-language press release. Sartorius shall not
assume any liability for the correctness of this translation. The
original German press release is the legally binding version.
Current image files
https://www.sartorius.com/en/company/newsroom/downloads-publications
Financial calendar
February
18, 2021: Annual press conference and publication of
the 2020 Annual Report
March 26, 2021: Virtual Annual
Shareholders' Meeting
April 21, 2021: Publication of
first-quarter figures (January to March 2021)
July 21, 2021: Publication of
first-half figures (January to June
2021)
October 20, 2021: Publication of
nine-month figures (January to September
2021)
About Sartorius
The Sartorius Group is a leading international partner of life
science research and the biopharmaceutical industry. With
innovative laboratory instruments and consumables, the Group's Lab
Products & Services Division concentrates on serving the needs
of laboratories performing research and quality control at pharma
and biopharma companies and those of academic research institutes.
The Bioprocess Solutions Division with its broad product portfolio
focusing on single-use solutions helps customers to manufacture
biotech medications and vaccines safely and efficiently. The Group
has been annually growing by double digits on average and has been
regularly expanding its portfolio by acquisitions complementary
technologies. In fiscal 2020, the company earned sales revenue of
some 2.34 billion euros according to its preliminary figures.
At the end of 2020, nearly 11,000 people were employed at the
Group's approximately 60 manufacturing and sales sites,
serving customers around the globe.
Follow Sartorius on Twitter @Sartorius_Group and on
LinkedIn.
Logo -
https://mma.prnewswire.com/media/1123369/Sartorius_Logo.jpg
Contact:
Timo
Lindemann
Group Spokesman
+49 (0)551 308 4724
timo.lindemann@sartorius.com
www.sartorius.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/resolutions-of-the-supervisory-board-of-sartorius-ag-301227180.html
SOURCE Sartorius AG